ArticlePediatrics international : official journal of the Japan Pediatric Society
Real-World Adrenaline Auto-Injector Use During Pediatric Anaphylaxis in Japan: A Single-Center Descriptive Study.
Article in Pediatrics international : official journal of the Japan Pediatric Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-World Shelf Life of Epinephrine Auto-Injectors in Canada: Implications for Renewal Frequency and Patient Burden.Journal of market access & health policy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough adrenaline auto-injector (AAI) prescribing has increased in Japan following insurance coverage expansion, real-world utilization during pediatric anaphylaxis remains insufficiently characterized. This study aimed to describe current AAI prescription patterns, actual utilization rates, and factors potentially associated with appropriate use.
methodsThis retrospective descriptive study analyzed AAI prescriptions and anaphylaxis hospitalizations at a tertiary care hospital in Shizuoka, Japan (2023-2024). We reviewed 124 AAI-prescribed children and 34 hospitalized anaphylaxis cases. For hospitalized patients possessing AAI (n = 8), we conducted detailed interviews assessing prior education quality, including hands-on training with expired AAI and smartphone application utilization.
resultsAmong 124 AAI-prescribed patients, only 5 (4.0%) used AAI during follow-up. Among 34 hospitalized anaphylaxis cases, more than half (55.9%) occurred on first known allergen exposure, particularly for seafood (92.9%). Only 8 patients (23.5%) possessed an AAI prior to the event; among them, 4 (50%) used their AAI. Notably, AAI use appeared to differ by concordance between the triggering allergen and the allergen for which AAI was prescribed: 4/5 (80%) used AAI when allergens matched versus 0/3 (0%) when they differed.
conclusionsThis study characterized current AAI prescription patterns and real-world utilization during pediatric anaphylaxis in Japan. Only 23.5% of hospitalized anaphylaxis cases possessed AAI, and utilization among possessors differed markedly depending on whether the triggering allergen matched the prescription indication. These findings suggest that AAI education should emphasize use for any anaphylaxis symptoms regardless of trigger.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.